Therapeutic Obinutuzumab antibody from the original Gazyvaro® commercial drug.
Product batch
| Expiry date
| Brand & Origin
| Price
| 1. Select quantity range | 2. Your quantity | |
|---|---|---|---|---|---|---|
2019.06 |
Gazyvaro® DE |
41,67 €
/mg
|
Select quantity:
|
mg |
||
2019.08 |
Gazyvaro® DE |
41,67 €
/mg
|
Select quantity:
|
mg |
Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API).
Here you will find the product information for the reference product.
| Drug name | Gazyvaro® |
| INN | Obinutuzumab |
| API type | Obinutuzumab is a Type II humanised anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanisation of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology |
| Pharmacotherapeutic group | Antineoplastic agents, monoclonal antibodies |
| ATC code | L01XC15 |
| Target of antibody | CD20; Synonyms: B1, Bp35, CVID5, LEU-16, MS4A2, S7, AA960661, Cd20, Ly-44, Ms4a2, MS4A1, bp35, cd20, ms4a2, leu-16, ms4a4c, cd20-like |
| General function | Obinutuzumab is used in the treatment of Chronic lymphocytic leukaemia and Follicular lymphoma. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Obinutuzumab is a recombinant monoclonal humanised and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype. It specifically targets the extracellular loop of the CD20 transmembrane antigen on the surface of non-malignant and malignant pre-B and mature B-lymphocytes, but not on haematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissue. Glycoengineering of the Fc part of obinutuzumab results in higher affinity for FcɣRIII receptors on immune effector cells such as natural killer (NK) cells, macrophages and monocytes as compared to nonglycoengineered antibodies. In nonclinical studies, obinutuzumab induces direct cell death and mediates antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) through recruitment of FcɣRIII positive immune effector cells. In addition, in vivo, obinutuzumab mediates a low degree of complement dependent cytotoxicity (CDC). Compared to Type I antibodies, obinutuzumab, a Type II antibody, is characterised by an enhanced direct cell death induction with a concomitant reduction in CDC at an equivalent dose. Obinutuzumab, as a glycoengineered antibody, is characterised by enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) compared to non-glycoengineered antibodies at an equivalent dose. In animal models obinutuzumab mediates potent B-cell depletion and antitumour efficacy. In the pivotal clinical study BO21004/CLL11, 91% (40 out of 44) of evaluable patients treated with Gazyvaro were B-cell depleted (defined as CD19+ B cell counts < 0.07 x 109/L) at the end of treatment period and remained depleted during the first 6 months of follow up. Recovery of B-cells was observed within 12-18 months of follow up in 35% (14 out of 40) of patients without progressive disease and 13% (5 out of 40) with progressive disease. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | |
| Original license holder | |
| Marketing authorisation numbers | EU/1/14/937/001 |
| Marketing authorisation holder | Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom |
| Name of the manufacturer of the biological active substance | Roche Diagnostics GmbH Nonnenwald 2 82377 Penzberg Germany |
| Name and address of the manufacturer(s) responsible for batch release | Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany |
| Max shelf life | 36 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | L-histidine L-histidine hydrochloride monohydrate Trehalose dihydrate Poloxamer 188 Water for injections |
Do you have any questions about the product, the ordering process or any other detail? Please contact us, we will reply within 24 hours.
At Evidentic, we deal with clinical-grade therapeutic molecules. Think of them as the building blocks for tomorrow’s groundbreaking treatments. These molecules are the active ingredients you’ll find in original drugs prescribed to patients, produced under the strictest quality and safety standards. They’ve also been therapeutically proven through rigorous clinical trials, meaning their effectiveness and safety for treating human diseases have been established. By offering researchers access to these essential tools, we’re fueling the fight for a healthier future.
Unlike some commercially available molecules, Evidentic’s clinical-grade therapeutics aren’t just research possibilities – they’re proven powerhouses! Derived from actual drugs used to treat human diseases, these molecules have already undergone rigorous testing and met the strictest safety and quality standards. This means researchers can focus their energy on groundbreaking discoveries, not questioning the reliability of their tools. With Evidentic, you get the confidence of knowing you’re working with the building blocks for real-world medical advancements.
If you struggle to source clinical-grade biologics you need for your research, Evidentic bridges the gap. We offer royalty-free research consumables (RUO-only) derived from original licensed drugs, giving you access to these critical research tools without the hassle.
But that’s not all. We understand the importance of batch variety in your research. That’s why we’ve built a comprehensive stock library, offering numerous batches of the same active pharmaceutical ingredient (API). This dedication to choice means you can find the exact batch that aligns with your specific research needs.
And because we’re constantly expanding our library, you can be sure we’re actively searching for new batches to add to your research arsenal. With Evidentic, unlock the power of readily available, high-quality research tools and accelerate your scientific breakthroughs.
Evidentic offers access to pharmaceuticals approved by the U.S. FDA (Food and Drug Administration) and/or the EMA (European Medicines Agency). This gives you access to a wider variety of molecules for your research, potentially shortening timelines and boosting the accuracy of your results. Compare EU and US molecules head-to-head, and accelerate your early drug development projects with access to these high-quality research tools. Contact us today to explore the possibilities!
Evidentic’s aliquots from approved pharnaceuticals can be used for analytical, in vitro research, typically executed in early drug development stage of drug discovery programs, like:
